A drug delivery platform will develop innovative solutions for the treatment of asthma and chronic obstructive pulmonary disease (COPD)
The acquisition will expand the new products’ pipeline
Milano, 6 august 2015– Zambon S.p.A., an international pharmaceutical company strongly committed in the Respiratory, the Rare Diseases and Central Nervous System area, today announced the acquisition of Eratech, a research and development Italian company with a strong pipeline in several therapeutic areas.
Thanks to Eratech, Zambon acquires a broad drug delivery platform based on an innovative technological approach which, by improving the deposition and distribution of pulmonary inhaled drugs, increases the clinical benefits and reduce side effects.
In this way Zambon will develop innovative products in other therapeutic areas such as the Central Nervous System, particularly in the treatment of the Parkinson's disease, one of the strategic areas in which the new drug Xadago ™ has recently been launched. Founded in 2002, Eratech is based in Piacenza and is active in the development of innovative inhalation drug delivery technologies, through highly engineered particles able to optimize the aerodynamic properties and lung deposition.
Maurizio Castorina, CEO of Zambon SpA stated: “The acquisition of Eratech represents for Zambon a significant investment towards a future technology, which will allow us to expand the pipeline with new products and to sign new partnerships, particularly in the US. With this agreement we also enter into a new technological environment, able to ensure the development of an incremental innovation both in asthma and in the COPD ".
About Zambon
Zambon is a leading Italian pharmaceutical and fine-chemical multinational business with a strong reputation for high quality products and services. The Group is strongly working on the treatment of the chronic respiratory diseases as asthma and COPD and on the CNS therapeutic area with Xadago® (safinamide), licensed by Newron, for the Parkinson treatment. Zambon is also well-established in 3 therapeutic areas: Respiratory, with a focus on Rare Disease and in particular on Cystic Fibrosis, Pain and Women’s care. Zambon SpA produces high quality products thanks to the management of the whole production chain which involves Zach (Zambon chemical), a privileged partner for API, custom synthesis and generic products. Headquartered in Milan and established in 1906 in Vicenza, Zambon has branches in 15 countries and more than 2,600 employees with manufacturing units in Italy, Switzerland, France, China and Brazil. Zambon products are commercialized in 84 countries. For details on Zambon please see: www.zambongroup.com
Eratech
Based in Piacenza, Eratech is a research and development company with a specific expertise in drug delivery technologies to get an optimized lung deposition. Founded in 2002 by John Caponetti, a researcher with 20 years of experience gained at MIT, as a founder of Advanced Inhalation Research (Cambridge, USA), then a researcher at Alkermes. The Eratech technology platform is focused on delivering engineered formulations of powders whose particles present drug delivery and bioavailability problems.
For further information
Media
Zambon
CCO
Luca Primavera
Phone: +39 02 66524491
Mobile: +39 335 7247417
Email: luca.primavera@zambongroup.com
